CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 35 enrolled
Drug / intervention
Timolol Maleate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03323164
NCT03323164Phase 4Completed
CompareCT.gov

Changes in Peripapillary Blood Flow After Use of Anti-glaucoma Medications: A Prospective, Quantitative OCT Angiography Study

Wills Eye·interventional·Posted Oct 26, 2017·Updated Dec 31, 2020

In Brief

A Phase 4 clinical trial evaluating Timolol Maleate and Brimonidine Tartrate for Glaucoma; Drugs and 2 related conditions. Completed, enrolled 35 participants across 1 site.

Detailed Summary

This study evaluates the possible acute changes in peripapillary blood flow after instillation of antiglaucoma medications in patients with primary open angle glaucoma (POAG), normal tension glaucoma (NTG), or ocular hypertension (OHTN) using Optical Coherence Tomography (OCT) angiography.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma
CountriesUnited States
CollaboratorsOptovue

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedOct 26, 2017
Enrollment StartJul 10, 2017
Primary CompletionDec 31, 2018
Study CompletionMay 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.7 years ago

Interventions

Timolol Maleatedrug

Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.

Brimonidine Tartratedrug

Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.